Why the study?
There is currently no commercially available vaccine against African swine fever, which is causing devastating outbreaks in the swine industry.
Key points are not available for this paper at this time.
Population
Pigs
Comparison
Infection with ASFV-G-ΔI177L followed by challenge with virulent parental virus
Design
Animal experimental study
Answers are grounded in this paper and cite their sources.
May advance ASFV vaccine development; leaves open protective efficacy and safety in swine.
Currently, there is no commercially available vaccine against African swine fever. Outbreaks of this disease are devastating the swine industry from Central Europe to East Asia, and they are being caused by circulating strains of African swine fever virus derived from the Georgia 2007 isolate. Here, we report the discovery of a previously uncharacterized virus gene, which when deleted completely attenuates the Georgia isolate. Importantly, animals infected with this genetically modified virus were protected from developing ASF after challenge with the virulent parental virus. Interestingly, ASFV-G-ΔI177L confers protection even at low doses (10 2 HAD 50 ) and remains completely attenuated when inoculated at high doses (10 6 HAD 50 ), demonstrating its potential as a safe vaccine candidate. At medium or higher doses (10 4 HAD 50 ), sterile immunity is achieved. Therefore, ASFV-G-ΔI177L is a novel efficacious experimental ASF vaccine protecting pigs from the epidemiologically relevant ASFV Georgia isolate.
No takes yet. Share an insight, caveat, or question.
Borca et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: